Incyte Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Bill Meury

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.2yrs

Jüngste Management Updates

Recent updates

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Aug 22 Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Geschäftsführer

Bill Meury (57 yo)

less than a year

Amtszeit

Mr. William Meury, also known as Bill, served as the Chief Executive Officer & Director of Anthos Therapeutics, Inc. since April 2024. He is CEO, President & Director of Incyte Corporation from June 26, 20...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pablo Cagnoni	President and Head of Research & Development	2.3yrs	US$7.90m	0.0026% $ 439.6k
Christiana Stamoulis	Executive VP & CFO	6.6yrs	US$5.40m	0.032% $ 5.3m
Herve Hoppenot	Advisor to CEO & Director	less than a year	US$17.46m	0.23% $ 38.0m
Steven Stein	Executive VP & Chief Medical Officer	10.5yrs	US$5.98m	0.0013% $ 219.0k
William Meury	CEO, President & Director	less than a year	keine Daten	keine Daten
Thomas Tray	VP of Finance	3.5yrs	keine Daten	0.0047% $ 782.3k
Michael Morrissey	Executive VP & Head of Global Technical Operations	9.7yrs	keine Daten	0.028% $ 4.6m
Greg Shertzer	Senior Director of Investor Relations	no data	keine Daten	keine Daten
Sheila Denton	Executive VP	1.9yrs	keine Daten	0.00034% $ 56.8k
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten
Soni Basi	Executive VP & Chief Human Resources Officer	less than a year	keine Daten	keine Daten
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0014% $ 239.0k

2.3yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: INCYDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Herve Hoppenot	Advisor to CEO & Director	11.7yrs	US$17.46m	0.23% $ 38.0m
William Meury	CEO, President & Director	less than a year	keine Daten	keine Daten
Jean-Jacques Bienaime	Independent Director	10.7yrs	US$518.15k	0.0094% $ 1.6m
Julian Baker	Independent Chairman of the Board	23.8yrs	US$552.15k	0.14% $ 23.9m
Otis Brawley	Independent Director	4yrs	US$494.15k	0.0045% $ 747.2k
Jacqualyn Fouse	Independent Director	8.7yrs	US$505.65k	0.0086% $ 1.4m
Edmund Harrigan	Independent Director	5.8yrs	US$521.65k	0.0091% $ 1.5m
Katherine High	Independent Director	5.5yrs	US$494.15k	0.0055% $ 926.0k
Paul Clancy	Independent Director	10.7yrs	US$519.15k	0.010% $ 1.7m
Susanne Schaffert	Independent Director	2.9yrs	US$503.88k	0.0025% $ 416.2k

7.2yrs

Durchschnittliche Betriebszugehörigkeit

64.5yo

Durchschnittliches Alter

Erfahrener Vorstand: INCYDie Vorstandsmitglieder gelten als erfahren (7.2 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/09/09 14:49
Aktienkurs zum Tagesende	2025/09/09 00:00
Gewinne	2025/06/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Incyte Corporation wird von 57 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Incyte Announces Executive Changes, Effective August 25, 2025

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Executive VP & Chief Medical Officer recently sold US$1.0m worth of stock

Insider recently sold US$743k worth of stock

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Recent updates

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte Announces Executive Changes, Effective August 25, 2025

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Price target increased by 7.2% to US$80.83

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Consensus EPS estimates increase by 18%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Executive VP & Chief Medical Officer recently sold US$1.0m worth of stock

Incyte Corporation to Report Q2, 2025 Results on Jul 29, 2025

Insider recently sold US$743k worth of stock

Incyte: New CEO Brings A New Possible Outcome

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Announces Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Incyte Announces FDA Approval of Monjuvi®? in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Corporation Announces FDA Approval of Zynyz (Retifanlimab-Llwr) Making It the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Revenue Guidance for the Year 2025

Incyte Corporation to Report Q1, 2025 Results on Apr 29, 2025

Insider recently sold US$1.3m worth of stock

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Lilly's baricitinib Delivered High Rates of Hair Regrowth for Adolescents with Severe Alopecia Areata in Phase 3 BRAVE-AA-PEDS Study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Medical Officer recently sold US$898k worth of stock

Incyte Corporation to Report Q4, 2024 Results on Feb 10, 2025

Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025

Incyte: Multiple Drug Launches Bode Well For Future Growth

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 13%

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar